Exelixis, Inc.

Exelixis, Inc.

Sector: Commercial Physical And Biological Research Region: CA, United States

: | Nasdaq: EXEL

Exelixis is a biopharmaceutical company committed to developing and commercializing small molecule therapies for the treatment of cancer. In advancing our first product, COMETRIQ, from discovery to market, we have established an effective and integrated infrastructure that encompasses the entire biopharmaceutical development continuum. We are committed to excellence in all aspects of our work and are dedicated to improving the care and outcome of cancer patients.

Latest Media

Warning! Third-party cookies must be enabled to view SlideShare presentations. ×

Having trouble?

Corporate Presentation

Exelixis, Inc. video

Corporate Presentation


Michael Morrissey, PhD, President and Chief Executive Officer
Michael M. Morrissey, Ph.D. has served as a director and as Exelixis’ President and Chief Executive Officer since July 2010. Dr. Morrissey has held positions of increasing responsibility at Exelixis since he joined the company in February 2000. From January 2007 until July 2010, he served as President of Research and Development, from January 2006 until December 2006, he served as Executive Vice President, Discovery, from January 2003 to December 2005, he served as Senior Vice President, Discovery, and from February 2000 through December 2002, he served as Vice President of Discovery Research. From 1991 to 2000, Dr. Morrissey held several positions at Berlex Biosciences, last holding the position of Vice President, Discovery Research. From 1986 to 1991, he served as a Senior Scientist and Project Team Leader in Medicinal Chemistry at CIBA-Geigy Corporation, a pharmaceutical company. He is the author of numerous scientific publications in medicinal chemistry and drug discovery and an inventor on 70 issued U.S. patents and 25 additional published U.S. patent applications. Dr. Morrissey holds a B.S. (Honors) in Chemistry from the University of Wisconsin and a Ph.D. in Chemistry from Harvard University.
Deborah Burke, Vice President and Interim Chief Financial Officer
Effective June 2, 2014, Deborah Burke, the Company’s Vice President, Finance and Controller, assumed the role of interim Chief Financial Officer until a permanent Chief Financial Officer is named. Ms. Burke has served as the Company’s Vice President, Finance & Controller since March 2011 and has held positions of progressive finance leadership since she joined the Company in May 2005, serving as Executive Director, Finance & Controller from March 2009 to February 2011, and as Senior Director, Finance & Controller from May 2005 to February 2009. From June 2004 to May 2005, Ms. Burke was an independent contractor providing financial and accounting services to the Company and other biotechnology and financial advisory companies. From December 2002 to May 2004, she held the position of business unit controller in the finance department of Celera Diagnostics, a molecular diagnostic company, where she was responsible for all of the company’s accounting and financial activities. Prior to that, she held roles of increasing responsibility in finance at Axys Pharmaceuticals and Khepri Pharmaceuticals, as well as audit and accounting roles at several nationally ranked independent public accounting firms. Ms. Burke is a Certified Public Accountant (inactive) and holds a B.S. in Accounting from Florida Atlantic University.
J. Scott Garland, Executive VP and Chief Commercial Officer
Scott Garland joined Exelixis as Executive Vice President and Chief Commercial Officer in October 2011. Mr. Garland is a biotechnology and pharmaceutical industry veteran with over 20 years of experience commercializing new compounds and building franchises for approved therapies. He joined Exelixis from Genentech, where, from 2009 to 2011, he served as vice president of the Avastin franchise. From 2007 to 2009, Mr. Garland served as vice president, hematology marketing and sales at Genentech, overseeing the Rituxan franchise, and from 2002 to 2007 served in other positions of increasing responsibility at Genentech. Before joining Genentech, Mr. Garland served in positions of increasing responsibility at Amgen and Merck. Mr. Garland received his MBA from Duke University’s Fuqua School of Business, and his bachelor’s degree from California Polytechnic University (San Luis Obispo).
Jeffrey J. Hessekiel, J.D., Executive Vice President and General Counsel
Jeffrey J. Hessekiel, J.D., has served as Executive Vice President and General Counsel since February 2014. Prior to joining Exelixis, Mr. Hessekiel was Senior Counsel at Arnold & Porter LLP, where he advised emerging growth and public companies, primarily in the life sciences sector, on complex legal issues connected with strategic transactions, healthcare compliance programs and investigations, and regulatory matters. Previously, from 2002 to 2012, he held key legal and compliance roles at Gilead Sciences, Inc., rising to the positions of Vice President, Commercial Legal Affairs and Litigation, and then Chief Compliance and Quality Officer. Prior to joining Gilead, Mr. Hessekiel trained in the litigation and corporate practice groups at a number of Silicon Valley law firms. He also worked for several international non-governmental organizations. Mr. Hessekiel received his J.D. from George Washington University’s School of Law, and his B.A. from Duke University.
Peter Lamb, PhD, Executive VP, Discovery Research and Chief Scientific Officer
Peter Lamb, Ph.D., has served as Executive Vice President, Discovery Research and Chief Scientific Officer since September 2009. Dr. Lamb previously served in numerous other positions since joining Exelixis in October 2000, including as Senior Director, Molecular Pharmacology and Structural Biology from October 2000 until December 2003, Vice President, Discovery Pharmacology from December 2003 until January 2007 and Senior Vice President, Discovery Research and Chief Scientific Officer from January 2007 until August 2009. From June 1992 until September 2000, Dr. Lamb held positions of increasing responsibility at Ligand Pharmaceuticals, most recently serving as Director of Transcription Research. Dr. Lamb has held post-doctoral research fellowships at the Carnegie Institution, Department of Embryology, with Dr. S.L. McKnight and the University of Oxford with Dr. N.J. Proudfoot, working in the field of gene regulation. Dr. Lamb has authored numerous articles in the fields of gene expression, signal transduction and oncology, and is an author on multiple issued and pending U.S. patents. Dr. Lamb has a Ph.D. in Molecular Biology from the ICRF/University of London and a B.A. in Biochemistry from the University of Cambridge.
Gisela M. Schwab, MD, Executive Vice President and Chief Medical Officer
Gisela M. Schwab, M.D., has served as Executive Vice President and Chief Medical Officer since January 2008. She joined Exelixis in 2006 as Senior Vice President and Chief Medical Officer. From 2002 to 2006, she held the position of Senior Vice President and Chief Medical Officer at Abgenix, Inc., a human antibody-based drug development company. She also served as vice president, clinical development, at Abgenix from 1999 to 2001. Prior to working at Abgenix, from 1992 to 1999, she held positions of increasing responsibility at Amgen Inc., most recently as Director of Clinical Research and Hematology/Oncology Therapeutic Area Team Leader. She received her Doctor of Medicine degree from the University of Heidelberg, trained at the University of Erlangen-Nuremberg and the National Cancer Institute and is board certified in internal medicine and hematology and oncology

News & Analysis